Anzeige
Mehr »
Login
Sonntag, 16.02.2025 Börsentäglich über 12.000 News von 686 internationalen Medien
1,5 Mio. Unzen indiziert, 5,2 Mio. Unzen geschätzt - und es wächst weiter: Die Goldaktie mit neuem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
14.02.25
20:19 Uhr
27,420 Euro
-0,100
-0,36 %
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
27,38027,64015.02.
27,38027,66014.02.

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.02.Swedish Orphan Biovitrum targets high single-digit growth in 2025 amid robust pipeline advancements6
05.02.Schwedische Orphan Biovitrum-Aktien sinken nach Q4-Ergebnissen2
05.02.Swedish Orphan Biovitrum shares dip on Q4 earnings3
05.02.Swedish Orphan Biovitrum AB Profit Climbs In Q42
05.02.Swedish Orphan Biovitrum AB: Sobi publishes Q4 2024 report: A solid ending to a strong year255STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024. Fourth Quarter 2024 Total revenue increased...
► Artikel lesen
01.02.Swedish Orphan Biovitrum Aktie: Auf dem Weg zur Marktführung422Die Swedish Orphan Biovitrum Aktie zeigt sich zu Beginn Februar 2025 in robuster Verfassung. Mit einem aktuellen Kurs von 29,07 EUR verzeichnet das Biotech-Unternehmen eine beachtliche Monatsentwicklung...
► Artikel lesen
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
28.01.SWEDISH ORPHAN BIOVITRUM AB: Sobi's latest haemophilia research to be presented at EAHAD 20254
21.01.Swedish Orphan Biovitrum AB: Invitation: Sobi's Q4 and FY 2024 report242Sobi plans to publish its report for the fourth quarter and full year of 2024 on 5 February 2025 at 08:00 CET. STOCKHOLM, Jan. 21, 2025 /PRNewswire/ -- Investors, analysts, and the media...
► Artikel lesen
13.01.Swedish Orphan Biovitrum shares rise following upgraded revenue forecast8
10.01.Swedish Orphan Biovitrum AB: Sobi's full year 2024 revenue higher than previous estimate738STOCKHOLM, Jan. 10, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year...
► Artikel lesen
13.12.24FDA accepts Sobi North America's thrombocytopenia therapy sNDA6
11.12.24Swedish Orphan Biovitrum AB: Bulletin from Sobi's Extraordinary General Meeting (EGM)303STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals...
► Artikel lesen
03.12.24Swedish Orphan Biovitrum AB: Sobi's strength in haematology to be showcased at ASH 2024357STOCKHOLM, Dec. 3, 2024 /PRNewswire/ -- New data from Sobi® and partners will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA (USA) from...
► Artikel lesen
11.11.24Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)331STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the...
► Artikel lesen
04.11.24Swedish Orphan Biovitrum AB: David Meek is proposed as new Chair of the Board of Directors of Sobi290The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary...
► Artikel lesen
30.10.24Swedish Orphan Biovitrum AB: New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference370STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's...
► Artikel lesen
27.10.24Swedish Orphan Biovitrum AB: Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN682Statistically significant 68% (pAll secondary endpoints favoured treatment with pegcetacoplan, including: - Stabilised eGFR, a key measure of kidney function- 71% of patients achieved...
► Artikel lesen
25.10.24Swedish Orphan Biovitrum AB: Invitation: Sobi's Aspaveli and the Phase 3 VALIANT data in Nephrology call272STOCKHOLM, Oct. 25, 2024 /PRNewswire/ -- VALIANT Phase 3 results after presentation at ASN Investors, analysts, and members of the media are invited to a conference call on Tuesday...
► Artikel lesen
25.10.24SWEDISH ORPHAN BIOVITRUM AB: Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call2
25.10.24Sobi meldet robustes Wachstum im dritten Quartal und hebt Prognose für 2024 an7
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1